Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Liver transplant (LT) centers may have variations in their approach to high-acuity (MELD ≥35) candidates for listing and transplantation. We investigated center-specific differences in waitlist outcomes, probability of LT, and post-LT survival in MELD ≥35 patients. Adult candidates of LT (MELD ≥35) were identified from the Scientific Registry of Transplant Recipients between January 1, 2010, and April 1, 2022. Waitlist mortality was modeled with the center as a random effect. Centers were grouped based on the random effect coefficient, with the highest tertile representing the highest risk group (comprises centers with the highest risk of waitlist mortality attributable to the center). Cumulative incidence of death/delisting, probability of LT, and 1-year post-LT survival were compared, with patients stratified by a listing MELD ≥35 or increase to MELD ≥35 after listing. In patients who increased to MELD ≥35, the 1-year cumulative incidence of death/delisting was highest (50%) and the probability of transplant lowest (46%) in the high-risk group, compared to the low-risk group (37% and 55%, p <0.001 for both comparisons). For patients receiving an LT, post-transplant survival did not differ among the groups, though high-risk centers transplanted far less high-acuity patients. These variations may indicate that certain centers are associated with substantially decreased waitlist mortality for the highest acuity patients without corresponding decreases in post-transplant survival.

Download full-text PDF

Source
http://dx.doi.org/10.1097/LVT.0000000000000616DOI Listing

Publication Analysis

Top Keywords

meld ≥35
24
waitlist mortality
12
liver transplant
8
post-lt survival
8
highest risk
8
cumulative incidence
8
incidence death/delisting
8
meld
7
≥35
6
center-level variations
4

Similar Publications

This research has proposed a new Emotion Recognition in Conversation (ERC) model known as Hierarchical Graph Learning for Emotion Recognition (HGLER), built to go beyond the existing approaches that find it difficult to request long-distance context and interaction across different data types. Rather than simply mixing different kinds of information, as is the case with traditional methods, HGLER uses a 2-part graph technique whereby conversations are represented in a 2-fold manner: one aimed at illustrating how various parts of the conversation relate and another for enhancing learning from various types of data. This dual-graph system can represent multimodal data value for value by exploiting the benefits of each type of data yet tracking their interactions.

View Article and Find Full Text PDF

Background: Steatotic liver diseases (SLDs) and their subcategories-metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD)-significantly contribute to liver-related and extrahepatic morbidity and mortality. This project aimed to assess the landscape of SLDs and clinically significant fibrosis (CSF) before (2017-2020) and during (2021-2023) the COVID-19 pandemic.

Methods: Using National Health and Nutrition Examination Survey (NHANES) data, we analyzed 8965 prepandemic and 6337 pandemic participants aged ≥18 years.

View Article and Find Full Text PDF

Introduction: The use of controlled-expansion transjugular intrahepatic portosystemic shunt (CX-TIPS) effectively controls portal hypertension (PH)-related complications while reducing risks related to fully expanded stents. We evaluated the effectiveness of CX-TIPS in a large Viennese patient cohort.

Method: We assessed the number of patients evaluated for CX-TIPS placement by interdisciplinary discussion at the Medical University of Vienna and included all patients from the prospective AUTIPS registry undergoing CX-TIPS placement between June 2018 - December 2024.

View Article and Find Full Text PDF

Introduction: Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are commonly prescribed. However, their comparative efficacy and safety remain unclear in HBV-ACLF.

View Article and Find Full Text PDF

Purpose: Although the clinical implication of sarcopenia has been verified in the context of cirrhosis, there is limited data concerning cut-offs of CT-measured skeletal muscle index (SMI) across different ethnicities. We aimed to compare the predictive performance of distinct SMI values-defined sarcopenia for prognosis in cirrhosis.

Methods: Totally, 478 inpatients due to cirrhosis-associated acute insults were prospectively enrolled.

View Article and Find Full Text PDF